1. Home
  2. BCDA vs SONM Comparison

BCDA vs SONM Comparison

Compare BCDA & SONM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCDA
  • SONM
  • Stock Information
  • Founded
  • BCDA N/A
  • SONM 1999
  • Country
  • BCDA United States
  • SONM United States
  • Employees
  • BCDA N/A
  • SONM N/A
  • Industry
  • BCDA Biotechnology: Pharmaceutical Preparations
  • SONM Telecommunications Equipment
  • Sector
  • BCDA Health Care
  • SONM Telecommunications
  • Exchange
  • BCDA Nasdaq
  • SONM Nasdaq
  • Market Cap
  • BCDA 11.0M
  • SONM 10.2M
  • IPO Year
  • BCDA N/A
  • SONM 2019
  • Fundamental
  • Price
  • BCDA $2.15
  • SONM $1.49
  • Analyst Decision
  • BCDA Strong Buy
  • SONM
  • Analyst Count
  • BCDA 1
  • SONM 0
  • Target Price
  • BCDA $25.00
  • SONM N/A
  • AVG Volume (30 Days)
  • BCDA 52.3K
  • SONM 11.6M
  • Earning Date
  • BCDA 08-12-2025
  • SONM 08-08-2025
  • Dividend Yield
  • BCDA N/A
  • SONM N/A
  • EPS Growth
  • BCDA N/A
  • SONM N/A
  • EPS
  • BCDA N/A
  • SONM N/A
  • Revenue
  • BCDA $3,000.00
  • SONM $58,243,000.00
  • Revenue This Year
  • BCDA N/A
  • SONM $127.68
  • Revenue Next Year
  • BCDA N/A
  • SONM N/A
  • P/E Ratio
  • BCDA N/A
  • SONM N/A
  • Revenue Growth
  • BCDA N/A
  • SONM N/A
  • 52 Week Low
  • BCDA $1.63
  • SONM $0.85
  • 52 Week High
  • BCDA $4.66
  • SONM $10.50
  • Technical
  • Relative Strength Index (RSI)
  • BCDA 51.13
  • SONM 59.58
  • Support Level
  • BCDA $1.98
  • SONM $0.97
  • Resistance Level
  • BCDA $2.45
  • SONM $2.08
  • Average True Range (ATR)
  • BCDA 0.17
  • SONM 0.30
  • MACD
  • BCDA 0.01
  • SONM 0.06
  • Stochastic Oscillator
  • BCDA 53.19
  • SONM 58.23

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

About SONM Sonim Technologies Inc.

Sonim Technologies Inc is a provider of ultra-rugged mobile devices, including phones and accessories designed specifically for task workers physically engaged in their work environments, often in mission-critical roles. The company sells mobile phones, accessories, and solutions to AT&T, T-Mobile, and Verizon in the Canada, and to Bell, Rogers, and Telus and Rogers, Telstra in Australia. The products include rugged mobile phones that can attach to both public and private wireless networks, industrial-grade accessories that meet the requirements of specific applications and software applications, and cloud-based tools that provide management and deployment services to customers. The company generates revenue from discounts, price protection, and customer incentives.

Share on Social Networks: